Update on the availability of FemSeven product range

Update on the availability of FemSeven product range

January 27, 2021

Following supply issues affecting the availability of the FemSeven range of products, Theramex, has provided the following update.

‘Theramex holds the marketing authorisation for FemSeven 50, 75 and 100® (estradiol), FemSeven Conti® (estradiol/levonorgestrel) and FemSeven Sequi® (estradiol/levonorgestrel) in the UK and Europe since acquiring these products from Teva Pharmaceuticals Ltd on 1st February 2018…We have since been working diligently to fix these issues and are pleased confirm that the entire FemSeven® portfolio of products will be returning in 2021 commencing with FemSeven Conti® which is available now from Alliance Healthcare.’

Further information

Theramex will continue to provide regular updates via its website.

The DHSC Medicine Supply Team provide a monthly update on potential supply issues affecting both primary and secondary care. This update is uploaded on the Specialist Pharmacy Services (SPS) website and anyone with an NHS email address can register with SPS to access the updates. NHSBSA also circulates directly to pharmacy NHSmail accounts a link to the monthly supply update hosted on the SPS website.

New shortages not listed on the SPS website, can be reported using our shortage reporting tool.

Please report your experiences of difficulties obtaining stock due to quota restrictions here

Posted in:

More Latest News >